Proteomics International Licenses US Sales of PromarkerD to PrismHealthDX

May 29, 2018

NEW YORK (360Dx) – Australian proteomics firm Proteomics International Laboratories said today it has licensed US sales of its PromarkerD test for diabetic kidney disease to PrismHealthDx (PHDx).

According to Proteomics International, Austin, Texas-based PHDx will roll out a national launch of the test, which uses mass spectrometry to measure blood-based proteins to predict diabetes patients' risk of developing diabetic kidney disease. PHDx will offer the test as a laboratory-developed test out of its CLIA facilities.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Breaking News

Feb

21

Featured Webinar

Case Study: 'Companion Informatics' to Automate Immunotherapy Manufacturing and Treatment

This webinar will provide a first-hand look at how Gradalis, a clinical-stage immunotherapy developer, is using an information management solution from L7 to streamline its research, clinical, and manufacturing operations.

Feb

26

Featured Webinar

A Cellular and Molecular Phenotyping Pipeline for Target Characterization in FFPE Biobank Samples

This webinar will demonstrate how a research team at the Firestone Institute for Respiratory Health at McMaster University developed a cellular and molecular phenotyping pipeline using archived samples of lung tissue derived from patients diagnosed with fibrotic interstitial lung disease.

Mar

20

Featured Webinar

A New Multiplex Syndromic System For Respiratory Diagnosis And Improved Patient Care

This webinar will discuss how a new multiplexed testing system can help physicians rapidly diagnose acute respiratory infections in the near-patient setting.

Main menu